LivaNova

Youtube Subscribe

Open: 46.42 Close: 45.8 Change: -0.62

The 8 top things that an AI found about LivaNova... they will surprise you

This document will help you to evaluate LivaNova without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about LivaNova are: LivaNova, year, PLC, Q3, revenue, shareholder, endure, and the …

Concept Map

Semantic Network

Stock Summary

LivaNova PLC designs, develops, manufactures, and sells therapeutic solutions. The Cardiopulmonary segment develops, produces, and markets cardiopul pulmonary products. Neuromodulation segment designs, markets VNS Therapy.

Today's Summary

LivaNova PLC reports 13.3% increase in Q3 revenue. Shareholders lost 2.5% in the last year, while the broader market gained around 15%.

Today's News

LivaNova PLC reports 13.3% increase in Q3 revenue. LivaNovas Q3 Beat and Future Outlook: Balancing Strong Cardiopulmonary Performance with Inflation Concerns and Leadership Transition. LivaNova PLC announces Bill Kozy, Interim CEO, will present at Piper Sandler Healthcare Conference in New York. The webcast will be available on www.livanova.com/events. A replay of the presentation will be able to be accessed within 90 days after the event. LivaNova shareholders have endured a 58% loss from investing in the stock five years ago. Shareholders lost 2.5% in the last year, while the broader market gained around 15%. In the last five years Livanova saw its revenue shrink by 0.7%. LivaNova (NASDAQ:LIVN) shareholders have endured a 58% loss from investing in the stock five years ago. The Vagus Nerve Stimulation Therapy (VNS Therapy) System, Symmetry™ for difficult-to-treat depression.

Stock Profile

"LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. It also engages in research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom."

Keywords

Are looking for the most relevant information about LivaNova? Investor spend a lot of time searching for information to make investment decisions in LivaNova. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about LivaNova are: LivaNova, year, PLC, Q3, revenue, shareholder, endure, and the most common words in the summary are: patient, livanova, trial, study, system, august, february, . One of the sentences in the summary was: Shareholders lost 2.5% in the last year, while the broader market gained around 15%.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #patient #livanova #trial #study #system #august #february.

Read more →

Youtube Subscribe

---